There has been much discussion lately about ever-increasing drug prices and the unsustainable financial burden they place on public health budgets. To address this, a new national drug agency has been proposed that would act as a central procurement point. Does this represent the most effective solution, or are there other models that could achieve lower drug costs and value for money for Canadian
Learn what Canada’s forward strategy for drug price negotiations could be and how it might be accomplished
• Learn what advantages and disadvantages multi-payer and single-payer systems represent
• Should there be any leeway given under a single-payer system to account for local population needs?
• Could the current system of evidence-based technology assessments stay the same or could it be streamlined under a different procurement model?
• If there is a move toward adopting a different procurement model, how might private payers respond?
Advance your understanding of the potential impact the new national drug agency could have on your organization.
The move toward the establishment of a national drug agency will cause some disruption to the normal approval process while its final structure takes shape. Get the insight you need to understand what changes may be on the horizon for new drug submissions. Walk away with knowledge that will help you:
Be on top of new developments for PLA submissions
Along with the public sector, private payers have also increased their scrutiny of the effectiveness and value for money represented by the drugs they approve for their formularies. Should a national pharmacare program be established, the use of pharmacoeconomics as an evaluative tool seems likely to increase, and provide greater harmonization between the standards of public and private payers for evaluating new drug submissions. Gain insight that will help you craft your market access strategy by learning:
Understand how private payer market access is changing and how you can adapt.
Ireland’s National Centre for Pharmacoeconomics conducts evaluations of medicines submitted for reimbursement and has a similar mandate to Canadian HTA agencies. Like other countries, the NCPE is also being challenged by evaluating the cost effectiveness of high-cost drugs, including biologics.
Gain insight into how this is being tackled outside North America by learning:
• How cost-effectiveness is evaluated within the Irish healthcare setting
• How the NCPE defines ‘significant budget impact’ and the criteria applied to new products to be subjected to the formal pharmacoeconomic assessment
• The NCPE’s approach to evaluating therapies for rare diseases
Understand how market access and reimbursement challenges are being met in a country with a healthcare system similar to Canada’s.
There are many possible approaches that could be taken to establishing a national pharmacare program. Understanding what direction is emerging from discussions among stakeholders as the most likely to taken once plans are actually underway, will be critical for your pricing and market access strategy. Gain insights for your organization through discussion about:
Hear the latest discussions and prepare your organization for the new era in pharmacare.
This session will take a data-driven approach to understand the latest market access trends. We will examine how long it is taking at each step of the access process from HTA to pCPA and listing. We will also examine the impact pre-NOC and other factors are having on this timeline, and discuss strategic implications to help market access managers prepare early for their launch.
In the face of constantly rising drug costs, employers are having to implement strategies to ensure their plans are sustainable. Learn what measures they are adopting to address skyrocketing drug prices. Walk away with actionable insights to inform your forward strategy by:
Ensure your market access plan has the best shot at success by understanding what employers need.
Canada’s relatively small market has been viewed as an obstacle to attracting drug R&D. That could change if a new approach were adopted that included incentives to conduct R&D in Canada.
Take back to your team insights to:
• Understand the incentives other countries have established that have proven successful in attracting R&D
• Discover whether there is value to offering incentives, whether they will encourage innovation, and if they will ultimately lead to lower drug costs
• Determine if there are economic arguments to offer incentives if they have a broader positive impact beyond drug costs for public health systems
Analyze what benefits could be gained by offering incentives to attract R&D to Canada.
New technology has enabled the development of drug/device and biologic combination products that target specific areas of the body and some which are genetically based. While these innovative therapies are more effective, determining the applicable regulation and path to market can be challenging. Gain insights to:
Anticipate and adapt to changes underway in the approval of combination products
With the recent federal announcement that the proposed changes to the PMPRB regulations are now a reality, assessing their impact and preparing for implementation will now become a priority. Gain in-depth information to elevate your understanding of the new drug pricing landscape. Walk away with an action plan to hone your market access strategy for Canada by learning:
Be sure your organization is prepared for this new market access reality
Continuing developments in personalized medicine are having a transformative impact on the lives of patients with rare diseases. The Care 4 Rare Research Program is on the forefront of this innovative shift in diagnosis and treatment. Take away insight to help you understand how the path to treatment is evolving for patients with rare diseases by learning:
Prepare your organization for the transformation precision medicine will bring
Developing, delivering and funding treatment for patients with rare diseases has become the single biggest challenge for payers, patients and manufacturers. With a growing consensus that a new drug development model is needed, the question becomes what form should it take? Get the latest on how this question may be resolved. Shape your strategy by hearing the latest views on:
Understand how the drug development model could fundamentally change for rare diseases.
Patients, healthcare providers, payers, purchasers, manufacturers; they all have a perspective and a voice. From drug R & D to regulators, your stakeholders influence your success. Learn the latest on experience design thinking, structured empathy, and co-creation in a fast-paced, hand-on workshop from an internationally recognized speaker.
Research on patient patterns of use and the effectiveness of medical cannabis has not kept pace with its rate of adoption by patients. The result is large gaps of knowledge about the types of patients who benefit most and its value as a substitute for pharmaceuticals such as opioids. Advance your game plan with insights to help you:
Be on top of the latest cross-sector developments in pharma and medical cannabis
The growth of the biosimilar market has been sluggish due to a number of reasons that include regulatory requirements, production costs, patient preferences and a reluctance on the part of some physicians to prescribe them. Yet as they represent significant cost savings, their adoption will only increase. Heighten your awareness of the increased market impact and future direction for biosimilars. Obtain useful insights to help you:
Improve the path to market for biosimilars and achieve lower treatment costs.
The new North American trade agreement extends data protection for biologics from 8 to 10 years. While this provides greater opportunities for Brand manufacturers, it may create greater push-back from payers trying to keep their costs at sustainable levels. Discover the probable outcome of this extended protection and fine-tune your strategy by learning:
Prepare your company for additional data protection for biologics under USMCA.
The pan-Canadian Pharmaceutical Alliance (pCPA) administers the formal process for getting new drugs to the marketplace. Source insights to manage and optimize your submission. Tap into both public and private perspectives in this interactive workshop and walk away with knowledge to:
Develop your successful pCPA strategy through this hands-on interactive workshop.
Your company has spent a decade or more and large amounts of money developing a new and promising treatment. The last thing you want to see is your product falling flat on the market with sales far below expectations. This session will provide a deep dive into the essentials for a successful launch.
Learn how to:
1. Differentiate your drug in the market pre and post launch
2. Coordinate across your organization to include market access,
patient services, medical and regulatory affairs, marketing and
sales for greatest impact
3. Understand and eliminate internal challenges that may impede
Make the most of your investment with a well-executed launch
Your product has been tested repeatedly during the clinical trial process and has been cleared to launch when shortly afterward, a patient reports and adverse reaction. Reporting is mandatory, and so is preserving your company’s stellar reputation for integrity as well as your investment.
Create a blueprint for managing adverse reaction reporting by:
1. Evaluating the reaction reported for severity and classification
2. Working with patient support groups to get ahead of the
problem and minimize impact
3. Learning how to prepare correct documentation and reports to
Health Canada and the Marketed Health Products Directorate
Don’t let an adverse reaction destroy your product’s positive reputation